IMCR
What one share of Immunocore Holdings holds
Biological Products, (No Diagnostic Substances)
We are a commercial stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases, and autoimmune diseases.
Immunocore Holdings’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $8.33 |
|---|---|
| Profit | −$0.35 |
| Capex (buildings and equipment) | $0.12 |
| Free cash flow | −$0.80 |
| Cash and investments | $17.10 |
| Book value | $8.15 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2021 | $0.86 | −$4.24 | $0.03 | −$3.40 | — | $5.33 |
| 2022 | $3.81 | −$1.15 | $0.05 | −$1.12 | $0.00 | $7.05 |
| 2023 | $5.10 | −$1.13 | $0.11 | −$0.05 | $0.00 | $7.42 |
| 2024 | $6.21 | −$1.02 | $0.10 | $0.42 | $0.00 | $7.21 |
| 2025 | $7.95 | −$0.71 | $0.09 | −$0.30 | $0.00 | $7.52 |